Genomic profiling for treating sarcoma patients
GENomic PROfilation for Therapeutic Purposes in SARComas and Molecular Tumor Board (MTB): Retrospective/Prospective Study in Referral Centers
Regina Elena Cancer Institute · NCT06076070
This study is testing if using genomic profiling can help find better treatment options for people with advanced sarcoma that can't be surgically removed.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Sex | All |
| Sponsor | Regina Elena Cancer Institute (other) |
| Locations | 1 site (Rome) |
| Trial ID | NCT06076070 on ClinicalTrials.gov |
What this trial studies
This multicenter observational study aims to evaluate the effectiveness of genomic profiling methods for therapeutic purposes in sarcoma patients with metastatic or locally advanced disease that is inoperable. It involves both retrospective and prospective assessments, utilizing the expertise of an institutional Molecular Tumor Board (MTB) to analyze patients who have no viable treatment alternatives or known driver mutations. The study includes patients of all ages and various histotypes of soft tissue and bone sarcomas, focusing on those at any stage of their treatment pathway.
Who should consider this trial
Good fit: Ideal candidates include sarcoma patients of any age with metastatic or locally advanced disease that is inoperable and without viable treatment options.
Not a fit: Patients with sarcoma who have already been treated with validated therapies or have operable disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide personalized treatment options for sarcoma patients who currently have limited therapeutic alternatives.
How similar studies have performed: Other studies utilizing genomic profiling for treatment decisions in cancer have shown promising results, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Sarcoma patients of any age (inclusion of centers pediatric) * Patients with any histotype of soft tissue sarcomas and bone * Patients at any stage of the treatment pathway for disease that is localized or metastatic/inoperable * Availability of follow-up data * Written informed consent (prospective part/patients in follow-up)
Where this trial is running
Rome
- "Regina Elena" National Cancer Institute — Rome, Italy (RECRUITING)
Study contacts
- Study coordinator: Virginia Ferraresi, MD
- Email: virginia.ferraresi@ifo.it
- Phone: 0652665144
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Sarcoma